Cited by 319Peroxisome Proliferator-Activated ReceptorsNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.

PPARs in the brain

HENEKA, M, LANDRETH, G·2007·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

DOI 10.1016/j.bbalip.2007.04.016

Open this paper in CoChat — free account

Abstract

The biology of peroxisome proliferator activated receptors (PPARs) in physiological and pathophysiological processes has been primarily studied in peripherial organs and tissues. Recently it became clear that PPARs play an important role for the pathogenesis of various disorders of the CNS. The finding that activation of PPARs, and in particular, the PPARgamma isoform, suppresses inflammation in peripherial macrophages and in models of human autoimmune disease, instigated the experimental evaluation of these salutary actions for several CNS disorders that have an inflammatory component. Activation of all PPAR isoforms, but especially of PPARgamma, has been found to be protective in murine in vitro and in vivo models of Multiple Sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in Multiple Sclerosis patients. Likewise, Alzheimer's disease has a prominent inflammatory component that arises in response to neurodegeneration and to extracellular deposition of beta-amyloid peptides. The fact that non steroidal anti-inflammatory drugs (NSAIDs) delay the onset and reduce the risk to develop Alzheimer's disease, while they also bind to and activate PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD may be mediated by PPARgamma. Several lines of evidence from in vitro and in vivo studies have supported this hypothesis, using Alzheimer disease related transgenic cellular and…

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2007.04.016

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,675
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,115
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523
World Cancer Report
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,389
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y., Ruiz‐Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,983
The WHO classification of tumors of the nervous system
Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,547
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,303
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,230
Peroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3216-3 · Cited by 1,222
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth
Rosen, E. D., & Spiegelman, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100034200 · Cited by 1,178
Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J. H., Berger, J. P., Chatterjee, K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,022
Immunological Aspects Of Demyelinating Diseases
Martinꝉ, R., McFarland, H. F., & McFarlin, D. E. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.001101 · Cited by 1,021
Emerging roles of PPARS in inflammation and immunity
Daynes, R. A., & Jones, D. C. (2002) · Nature reviews. Immunology · doi:10.1038/nri912 · Cited by 926
Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics
Barone, F. C., & Feuerstein, G. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199908000-00001 · Cited by 924
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
Su, C. G., Wen, X., Bailey, S. T., Jiang, W. G., Rangwala, S. M., Keilbaugh, S. A., Flanigan, A., Murthy, S., Lazar, M. A., & Wu, G. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7145 · Cited by 769
Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients
Auboeuf, D., Rieusset, J., Lluis Fajas, A., Vallier, P., Fréring, V., Riou, J. P., Staels, B., Auwerx, J. H., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 699
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Diabetes Mellitus and Risk of Alzheimer's Disease and Dementia with Stroke in a Multiethnic Cohort
Luchsinger, J. A. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.7.635 · Cited by 682
Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease
Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, É. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ)
Peters, J. M., Lee, S. S. T., Li, W., Ward, J. M., Gavrilova, O., Grueter, C. A., Reitman, M. L., Hudson, L. D., & Gonzalez, F. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5119-5128.2000 · Cited by 644
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 641
Pattern formation by local self-activation and lateral inhibition
Meinhardt, H., & Gierer, A. (2000) · BioEssays · doi:10.1002/1521-1878(200008)22:8 · Cited by 629
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Przedborski, S., Jackson-Lewis, V. R., Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624
Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone
Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 614
Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS
Moreno, S., Vecchioli, S. F., & Cerù, M. P. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 595
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 590
Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Self-citation
Parallel SUMOylation-Dependent Pathways Mediate Gene- and Signal-Specific Transrepression by LXRs and PPARγ
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561
Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis
Qiu, W. Q., & Folstein, M. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.004 · Cited by 557
Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat
Relton, J. K., & Rothwell, N. J. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90033-t · Cited by 548
Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Self-citation
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E. J., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 481
Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding
Escher, P., Braissant, O., Modak, S. B., Michalik, L., Wahli, W., & Desvergne, B. (2001) · Endocrinology · doi:10.1210/endo.142.10.8458 · Cited by 473
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
Self-citation
Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer
Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M. M., Englaro, W., Schoonjans, K., Dérijard, B., Desvergne, B., Wahli, W., Chambon, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.827 · Cited by 459
Differential Expression of Peroxisome Proliferator-Activated Receptor- , - , and - during Rat Embryonic Development
Braissant, O., & Wahli, W. (1998) · Endocrinology · doi:10.1210/endo.139.6.6049 · Cited by 457
Peroxisome proliferator activated receptor-alpha expression in human liver.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 442
Self-citation
Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study
Kuusisto, J., Koivisto, K. J., Mykkänen, L. M., Helkala, E.-L., Vanhanen, M., Hänninen, T., Kervinen, K., Kesäniemi, Y. A., Riekkinen, P. J., & Laakso, M. (1997) · BMJ · doi:10.1136/bmj.315.7115.1045 · Cited by 426
Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons
Hantraye, P., Brouillet, E., Ferrante, R. J., Palfi, S., Dolan, R., Matthews, R. T., & Beal, M. F. (1996) · Nature Medicine · doi:10.1038/nm0996-1017 · Cited by 422
Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists
Mukherjee, R., Jow, L., Croston, G. E., & Paterniti, J. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.8071 · Cited by 421
Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020936.x · Cited by 417
The Role of Insulin Resistance in the Pathogenesis of Alzheimer??s Disease
Watson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 400
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation
Dehmer, T., Heneka, M. T., Sastre, M., DICHGANS, J., & Schulz, J. B. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 387
Self-citation
Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G. E., Launay, J., & Hirsch, É. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 381
Self-citation
15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
Kawahito, Y., Kondo, M., Tsubouchi, Y., Hashiramoto, A., Bishop‐Bailey, D., Inoue, K., Kohno, M., Yamada, R., Hla, T., & Sano, H. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9652 · Cited by 374
Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373
Self-citation
Anti‐ICAM‐1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat
Zhang, R. L., Chopp, M., Li, Y., Zaloga, C., Jiang, N., Jones, M. L., Miyasaka, M., & Ward, P. A. (1994) · Neurology · doi:10.1212/wnl.44.9.1747 · Cited by 362
Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase
Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., LEUVEN, F. V., & Heneka, M. T. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09796.2003 · Cited by 361
Self-citation
Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo
Dehmer, T., Lindenau, J. H., Haid, S., DICHGANS, J., & Schulz, J. B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742213.x · Cited by 337
PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes
Marx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Köenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 336
Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity
Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., Helwig, A., & Poser, S. (1995) · Annals of Neurology · doi:10.1002/ana.410370115 · Cited by 334
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 320
Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.
Palakurthi, S. S., Aktaş, H., Grubissich, L., Mortensen, R. M., & Halperin, J. A. (2001) · PubMed · Cited by 301
Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion
Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.049 · Cited by 300
Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells
Marx, N., Mach, F., Sauty, A., Leung, J. H., Sarafi, M. N., Ransohoff, R. M., Libby, P., Plutzky, J., & Luster, A. D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6503 · Cited by 297
Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B., Kliewer, S. A., Lehmann, J. M., & Morris, D. C. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09536-7 · Cited by 295
Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitis
Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G. L., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294
Self-citation
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
Yoram Vodovotz, B., Lucia, M. S., Flanders, K. C., Chesler, L., Xie, Q. W., Smith, T. W., Weidner, J. R., Mumford, R. A., Webber, R., Nathan, C., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.4.1425 · Cited by 292
Post-ischemic inflammation: molecular mechanisms and therapeutic implications
Zheng, Z., & Yenari, M. A. (2004) · Neurological Research · doi:10.1179/016164104x2357 · Cited by 290
Peroxisome Proliferator-Activated Receptor-γ Agonist 15-Deoxy-Δ12,1412,14-Prostaglandin J2 Ameliorates Experimental Autoimmune Encephalomyelitis
Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett‐Racke, A. E., Drew, P. D., & Racke, M. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2508 · Cited by 287
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Peroxisome Proliferator-Activated Receptor-γ Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell DeathIn Vivo
Heneka, M. T., Klockgether, T., & Feinstein, D. L. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06862.2000 · Cited by 269
Self-citation
Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia
Sundararajan, S., Gamboa, J. L., Victor, N., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266
Self-citation
Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors
Cunard, R. A., Ricote, M., DiCampli, D., Archer, D. C., Kahn, D. A., Glass, C. K., & Kelly, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2795 · Cited by 238
Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice
Inoue, H., Jiang, X., Katayama, T., Osada, S., Umesono, K., & Namura, S. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.001 · Cited by 238
Inhibition of Inducible Nitric Oxide Synthase by Peroxisome Proliferator-Activated Receptor Agonists: Correlation with Induction of Heme Oxygenase 1
Colville‐Nash, P., Qureshi, S. S., Willis, D., & Willoughby, D. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.978 · Cited by 237
PRIMARY BRAIN TUMORS IN ADULTS
Chandana, S. R., Movva, S., Arora, M. L., & Singh, T. (1994) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/00132979-199401020-00005 · Cited by 235
Distribution of mRNAs Encoding the Peroxisome Proliferator‐Activated Receptor α, β, and γ and the Retinoid X Receptor α, β, and γ in Rat Central Nervous System
Cullingford, T. E., Bhakoo, K. K., Peuchen, S., Dolphin, C. T., Patel, R., & Clark, J. B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041366.x · Cited by 234
PPAR-γ Agonists as Regulators of Microglial Activation and Brain Inflammation
Bernardo, A., & Minghetti, L. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206780574579 · Cited by 227
The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice
Schütz, B., Reimann, J., Dumitrescu‐Ozimek, L., Kappes‐Horn, K., Landreth, G. E., Schürmann, B., Zimmer, A., & Heneka, M. T. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2038-05.2005 · Cited by 225
Self-citation
Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment
Deplanque, D., Gelé, P., Pétrault, O., Six, I., Furman, C., Bouly, M., Nion, S., Dupuis, B., Leys, D., Fruchart, J., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06264.2003 · Cited by 219
A Peroxisome Proliferator-Activated Receptor-γ Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia
Shimazu, T., Inoue, I., Araki, N., Asano, Y., Sawada, M., Furuya, D., Nagoya, H., & Greenberg, J. H. (2004) · Stroke · doi:10.1161/01.str.0000152271.21943.a2 · Cited by 218
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis
Kiaei, M., KIPIANI, K., CHEN, J., Calingasan, N. Y., & Beal, M. F. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.10.007 · Cited by 215
Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells
Wang, N., Verna, L. K., Chen, N.-G., Chen, J., Li, H., FORMAN, B. M., & Stemerman, M. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203436200 · Cited by 210
Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone
Luo, Y., Yin, W., Signore, A. P., Zhang, F., Hong, Z., Wang, S., Graham, S. H., & Chen, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03758.x · Cited by 206
Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease
Lovett‐Racke, A. E., Hussain, R. Z., Northrop, S. C., Choy, J., Rocchini, A., Matthes, L., Chavis, J. A., Diab, A., Drew, P. D., & Racke, M. K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5790 · Cited by 206
Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype
Craft, S., Asthana, S., Schellenberg, G., Baker, L., Cherrier, M., Boyt, A. A., Martins, R., Raskind, M., Peskind, E., & Plymate, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06371.x · Cited by 200
Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ Activation
Luna‐Medina, R., Cortés‐Canteli, M., Alonso, M., Santos, Á., Martı́nez, A., & Pérez‐Castillo, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414390200 · Cited by 191
Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling
Inestrosa, N. C., Godoy, J. A., Quintanilla, R. A., KOENIG, C., & Bronfman, M. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.09.032 · Cited by 191
Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ
Niino, M., Iwabuchi, K., Kikuchi, S., Ato, M., Morohashi, T., Ogata, A., Tashiro, K., & Onoé, K. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00285-5 · Cited by 188
PPAR ? agonists stimulate oligodendrocyte differentiation in tissue culture
Saluja, I., Granneman, J. G., & Skoff, R. P. (2001) · Glia · doi:10.1002/1098-1136(200103)33:3 · Cited by 186
Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain
Chopp, M., Li, Y., Jiang, N., Zhang, R. L., & Prostak, J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199607000-00007 · Cited by 185
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Espuny-Camacho, I., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D. I., & Strooper, B. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 171
Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease
Landreth, G. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169
Self-citation
Inhibition of TNFα attenuates infarct volume and ICAM-1 expression in ischemic mouse brain
Yang, G., Gong, C., Qin, Z., Ye, W., Mao, Y. Q., & Bertz, A.-K. (1998) · Neuroreport · doi:10.1097/00001756-199806220-00041 · Cited by 166
Peroxisome Proliferator-activated Receptor γ-mediated Regulation of Neural Stem Cell Proliferation and Differentiation
Wada, K., Nakajima, A., Katayama, K., Kudo, C., Shibuya, A., Kubota, N., Terauchi, Y., Tachibana, M., Miyoshi, H., Kamisaki, Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513786200 · Cited by 165
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-α agonist WY14643
Collino, M., Aragno, M., Mastrocola, R., Benetti, E., Gallicchio, M., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.04.030 · Cited by 163
Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., Plymate, S., Latendresse, S., Petrova, A., Raskind, M., et al. (1999) · Neuroendocrinology · doi:10.1159/000054469 · Cited by 154
Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase
Heneka, M. T., L. Feinstein, D., Galea, E., Gleichmann, M., Wüllner, U., & Klockgether, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00192-7 · Cited by 150
Self-citation
Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease
Heneka, M. T., Wiesinger, H., Dumitrescu‐Ozimek, L., Riederer, P. F., Feinstein, D. L., & Klockgether, T. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.9.906 · Cited by 148
Self-citation
Interferon-γ-induced Regulation of Peroxisome Proliferator-activated Receptor γ and STATs in Adipocytes
Waite, K. J., Floyd, Z. E., Arbour-Reily, P., & Stephens, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007894200 · Cited by 145
Noradrenergic depletion increases inflammatory responses in brain: effects on IκB and HSP70 expression
Heneka, M. T., Gavrilyuk, V., Landreth, G. E., O’Banion, M. K., Weinberg, G. L., & Feinstein, D. L. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01694.x · Cited by 144
Self-citation
Effects of peroxisome proliferator‐activated receptor‐γ agonists on central nervous system inflammation
Kielian, T., & Drew, P. D. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10501 · Cited by 143
Altered PPARγ expression and activation after transient focal ischemia in rats
Victor, N., Wanderi, E. W., Gamboa, J. L., Zhao, X., Aronowski, J. A., Deininger, K. M., Lust, W. D., Landreth, G. E., & Sundararajan, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05037.x · Cited by 143
Self-citation
Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor δ-Selective Agonists in Vitro and in Vivo
Iwashita, A., Muramatsu, Y., Yamazaki, T., Muramoto, M., Kita, Y., Yamazaki, S., Mihara, K., Moriguchi, A., & Matsuoka, N. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.115758 · Cited by 140
Untitled work
(1997) · PubMed · Cited by 139
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2
Kim, E. J., Kwon, K. J., Park, J.-Y., Lee, S., Moon, C., & Baik, E. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02480-0 · Cited by 137
Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ
Zander, T., Kraus, J. A., Grommes, C., Schlegel, U. S., Feinstein, D. L., Klockgether, T., Landreth, G. E., Koenigsknecht-Talboo, J., & Heneka, M. T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00899.x · Cited by 135
Self-citation
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
Kintscher, U., Goetze, S., Wakino, S., Kim, S., Nagpal, S., Chandraratna, R. A. S., Graf, K., Fleck, E., Hsueh, W. A., & Law, R. E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00461-1 · Cited by 132
Glitazones Differentially Regulate Primary Astrocyte and Glioma Cell Survival
Pérez‐Ortiz, J. M., Tranque, P., Vaquero, C. F., Domingo, B., Molina, F., Calvo, S., Jordán, J., Ceña, V., & Llopis, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308518200 · Cited by 130
Peroxisome Proliferator-activated Receptor β Regulates Acyl-CoA Synthetase 2 in Reaggregated Rat Brain Cell Cultures
Modak, S. B., Braissant, O., Escher, P., Desvergne, B., Honegger, P., & Wahli, W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35881 · Cited by 130
Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease
Fuentealba, R. A., Farı́as, G. G., Scheu, J., Bronfman, M., Marzolo, M., & Inestrosa, N. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.018 · Cited by 126
Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis
Polak, P. E., Kalinin, S., Russo, C. D., Gavrilyuk, V., Sharp, A. J., Peters, J. M., Richardson, J. C., Willson, T. M., Weinberg, G. L., & Feinstein, D. L. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.07.006 · Cited by 125
An overview of the effect of linoleic and conjugated‐linoleic acids on the growth of several human tumor cell lines
Maggiora, M., Bologna, M., Cerù, M. P., Possati, L., Angelucci, A., Cimini, A., Miglietta, A., Bozzo, F., Margiotta, C., Muzio, G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20519 · Cited by 121
Inflammation and acute stroke
Becker, K. J. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199802000-00008 · Cited by 120
Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons
Woods, J. W., Tanen, M., Figueroa, D. J., Biswas, C., Zycband, E., Moller, D. E., Austin, C. P., & Berger, J. P. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02515-0 · Cited by 113
Inducible Nitric Oxide Synthase Immunoreactivity in the Alzheimer Disease Hippocampus: Association with Hirano Bodies, Neurofibrillary Tangles, and Senile Plaques
Lee, S. C., Zhao, M., Hirano, A., & Dickson, D. W. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199911000-00006 · Cited by 112
Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke
Barone, F. C., Hillegass, L. M., Tzimas, M. N., Schmidt, D. B., Foley, J. J., White, R. F., Price, W. J., FEUERSTEIN, G. Z., Clark, R. K., Griswold, D. E., et al. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160109 · Cited by 111
Molecular Pathology of Cerebral Ischemia: Delayed Gene Expression and Strategies for Neuroprotectiona
Iadecola, C., & Ross, M. E. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48631.x · Cited by 109
Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease
PEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108
Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms
Pereira, M. P., Hurtado, O., Cárdenas, A., Boscá, L., Castillo, J., Dávalos, A., Vivancos, J., Serena, J. L., Lorenzo, P. L., Lizasoaín, I., et al. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600182 · Cited by 107
The intracerebral application of the PPARγ‐ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain
Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., & Čulman, J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04200.x · Cited by 106
Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway
Park, K. S., Lee, R. D., Kang, S.-K., Han, S. Y., Park, K. L., Yang, K. H., Song, Y. S., Park, H. J., Lee, Y. M., Yun, Y. P., et al. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.03.034 · Cited by 105
Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPAR? agonists as inducers of apoptosis
Chattopadhyay, N., Singh, D. P., Heese, O., Godbole, M. M., Shinohara, T., Black, P. M., & Brown, E. M. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000701)61:1 · Cited by 103
Peroxisome Proliferator-Activated Receptor-γ-Deficient Heterozygous Mice Develop an Exacerbated Neural Antigen-Induced Th1 Response and Experimental Allergic Encephalomyelitis
Bright, J. J., Natarajan, C., Muthian, G., Barak, Y., & Evans, R. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5743 · Cited by 102
Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor γ Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients
Klotz, L., Schmidt, M., Giese, T., Sastre, M., Knolle, P. A., Klockgether, T., & Heneka, M. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.4948 · Cited by 102
Self-citation
Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor γ Agonist Treatment
Grommes, C., Landreth, G. E., Sastre, M., Beck, M., Feinstein, D. L., Jacobs, A. H., Schlegel, U. S., & Heneka, M. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022194 · Cited by 98
Self-citation
Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients
Schmidt, S., Moric, E., Schmidt, M., Sastre, M., Feinstein, D. L., & Heneka, M. T. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0803402 · Cited by 96
Self-citation
WY14,643, a PPARα Ligand, Has Profound Effects on Immune Responses In Vivo
Cunard, R. A., DiCampli, D., Archer, D. C., Stevenson, J. L., Ricote, M., Glass, C. K., & Kelly, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6806 · Cited by 96
Peroxisome-proliferator-activated receptor-gamma (PPARγ) activation protects neurons from NMDA excitotoxicity
Zhao, X., Ou, Z., Grotta, J. C., Waxham, M. N., & Aronowski, J. A. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.061 · Cited by 91
Peroxisome proliferator activated receptor agonists
Kersten, S., & Wahli, W. (2000) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-8393-1_9 · Cited by 89
Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis
Weydt, P., & ̈ller, T. M. (2005) · Neuroreport · doi:10.1097/00001756-200504250-00001 · Cited by 84
Peroxisome proliferator-activated receptor-?: therapeutic target for diseases beyond diabetes: quo vadis?
Pershadsingh, H. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.215 · Cited by 83
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
Kreisler, A., Gelé, P., Wiart, J., Lhermitte, M., Destée, A., & Bordet, R. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.011 · Cited by 82
Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes
Cristiano, L., Bernardo, A., & Ceru`, M. P. (2001) · Journal of Neurocytology · doi:10.1023/a:1016525716209 · Cited by 81
Role of peroxisome proliferator-activated receptor γ in amyloid precursor protein processing and amyloid β-mediated cell death
d’Abramo, C., Massone, S., Zingg, J.-M., Pizzuti, A., Marambaud, P., Piccola, B. D., Azzi, A., Marinari, U. M., Pronzato, M. A., & Ricciarelli, R. (2005) · Biochemical Journal · doi:10.1042/bj20050560 · Cited by 81
Pathways of Inflammatory Activation in Alzheimers Disease: Potential Targets for Disease Modifying Drugs
Hüll, M., Lieb, K. P., & Fiebich, B. L. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023371292 · Cited by 80
Increased Infarct Size and Lack of Hyperphagic Response after Focal Cerebral Ischemia in Peroxisome Proliferator-Activated Receptor β-Deficient Mice
Arsenijevic, D., de Bilbao, F., Plamondon, J., Paradis, É., Vallet, P., Richard, D., Langhans, W., & Giannakopoulos, P. (2006) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/sj.jcbfm.9600200 · Cited by 79
Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells.
Han, S. W., Greene, M. E., Pitts, J., Wada, R. K., & Sidell, N. (2001) · PubMed · Cited by 77
The Nonthiazolidinedione PPARγ Agonist L-796,449 Is Neuroprotective in Experimental Stroke
Pereira, M. P., Hurtado, O., Cárdenas, A., Alonso‐Escolano, D., Boscá, L., Vivancos, J., Nombela, F., Leza, J. C., Lorenzo, P. L., Lizasoaín, I., et al. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178852.83680.3c · Cited by 76
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin
Schultze, K., Böck, B. C., Eckert, A., Oevermann, L., Ramacher, D., Wiestler, O. D., & Roth, W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-8896-3 · Cited by 72
A Peroxisome Proliferator-activated Receptor-γ Agonist, Troglitazone, Facilitates Caspase-8 and -9 Activities by Increasing the Enzymatic Activity of Protein-tyrosine Phosphatase-1B on Human Glioma Cells
Akasaki, Y., Liu, G., Matundan, H. H., Ng, H., Yuan, X., Zeng, Z., Black, K. L., & Yu, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505266200 · Cited by 72
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone
Yao, C., Lai, G., Chan, C., Cheng, A., Yang, Y., & Chuang, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21361 · Cited by 70
Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease
Keller, J. M., Collet, P., Bianchi, A., Huin‐Schohn, C., Krémarik, P., Bécuwe, P., Schohn, H., Domenjoud, L., & Dauça, M. (2000) · The International Journal of Developmental Biology · doi:10.1387/ijdb.11032176 · Cited by 70
Transcription Suppression of Peroxisome Proliferator-Activated Receptor γ2 Gene Expression by Tumor Necrosis Factor α via an Inhibition of CCAAT/ Enhancer-binding Protein δ during the Early Stage of Adipocyte Differentiation
Kudo, M., Sugawara, A., Uruno, A., Takeuchi, K., & Ito, S. (2004) · Endocrinology · doi:10.1210/en.2004-0180 · Cited by 69
Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
Straková, N., Ehrmann, J., Bartoš, J., Malíková, J., Doležel, J., & Kolar, Z. (2005) · PubMed · Cited by 65
Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways
Berge, K., Tronstad, K. J., Flindt, E. N., Rasmussen, T. H., Madsen, L., Kristiansen, K., & Berge, R. K. (2001) · Carcinogenesis · doi:10.1093/carcin/22.11.1747 · Cited by 64
The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-γ Ciglitazone Affects Human Glioblastoma Cell Lines
Straková, N., Ehrmann, J., Džubák, P., Bouchal, J., & Kolář, Z. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063438 · Cited by 63
The PPARγ ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines
Roberta Morosetti, A., Servidei, T., Massimiliano Mirabella, A., Rutella, S., Mangiola, A., Maira, G., Mastrangelo, R., & Koeffler, H. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.2.493 · Cited by 61
TNFα downregulates PPARδ expression in oligodendrocyte progenitor cells: Implications for demyelinating diseases
Cimini, A., Bernardo, A., Cifone, M. G., Marzio, L. D., & Loreto, S. D. (2002) · Glia · doi:10.1002/glia.10143 · Cited by 60
PPARγ‐dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)
Cimini, A., Cristiano, L., Colafarina, S., Benedetti, E., Loreto, S. D., Festuccia, C., Amicarelli, F., Canuto, R. A., & Cerù, M. P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21272 · Cited by 55
A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.
Liu, D., Zang, C., Liu, H., Possinger, K., Fan, S.-G., & Elstner, E. (2004) · PubMed · Cited by 53
PPARγ antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-Deoxy-Δ12,14-Prostaglandin J2
Raikwar, H. P., Muthian, G., Rajasingh, J., Johnson, C., & Bright, J. J. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.05.013 · Cited by 51
Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity
Barish, G. D. (2006) · Journal of Nutrition · doi:10.1093/jn/136.3.690 · Cited by 50
Antiinflammatory properties of PPARgamma agonists following ischemia
Sundararajan, S., & Landreth, G. E. (2004) · Drug News & Perspectives · doi:10.1358/dnp.2004.17.4.829049 · Cited by 50
Self-citation
Effects of Thiazolidinediones on Stroke Recovery: A Case-Matched Controlled Study
Lee, J., & REDING, M. J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9138-3 · Cited by 49
Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2.
Chen, S.-D., Wu, H.-Y., Yang, D.-I., Lee, S.-Y., Shaw, F.-Z., Lin, T.-K., Liou, C., & Chuang, Y.-C. (2006) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2006.10.017 · Cited by 47
Effect of the peroxisome proliferator‐activated receptor β activator GW0742 in rat cultured cerebellar granule neurons
Smith, S. A., Monteith, G. R., Robinson, J. A., Venkata, N. G., May, F. J., & Roberts‐Thomson, S. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20153 · Cited by 43
Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system
Vecchioli, S. F., Moreno, S., & Cerù, M. P. (2001) · Journal of Neurocytology · doi:10.1023/a:1011913223541 · Cited by 38
Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro
Valentiner, U., Carlsson, M., Erttmann, R., Hildebrandt, H., & Schumacher, U. (2005) · Toxicology · doi:10.1016/j.tox.2005.05.024 · Cited by 35
ROSIGLITAZONE, A PEROXISOME PROLIFERATOR‐ACTIVATED RECEPTOR‐γ LIGAND, REDUCES INFARCTION VOLUME AND NEUROLOGICAL DEFICITS IN AN EMBOLIC MODEL OF STROKE
Allahtavakoli, M., Shabanzadeh, A. P., Sadr, S. S., Parviz, M., & DJAHANGUIRI, B. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04486.x · Cited by 33
Peroxisome proliferator-activated receptors (PPARs) in health and disease.
Ehrmann, J., Vavrušová, N., Collan, Y. U., & Kolář, Z. (2002) · Biomedical Papers · doi:10.5507/bp.2002.002 · Cited by 32
Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
Cellai, I., Benvenuti, S., Luciani, P., Galli, A., Ceni, E., Simi, L., Baglioni, S., Muratori, M., Ottanelli, B., Serio, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603344 · Cited by 31
Expression of PPARγ and Its Ligand‐dependent Growth Inhibition in Human Brain Tumor Cell Lines
Kato, M., Nagaya, T., Fujieda, M., Saito, K., Yoshida, J., & Seo, H. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01304.x · Cited by 31
Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes
Lee, B. C., Lee, H., & Chung, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.024 · Cited by 30
The human semaphorin 6B gene is down regulated by PPARs
Collet, P., Domenjoud, L., Devignes, M., Murad, H., Schohn, H., & Dauça, M. (2004) · Genomics · doi:10.1016/j.ygeno.2004.01.002 · Cited by 29
The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor γ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells
Grommes, C., Landreth, G. E., Schlegel, U. S., & Heneka, M. T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078972 · Cited by 28
Self-citation
Overexpression of wild-type RhoA produces growth arrest by disrupting actin cytoskeleton and microtubules
Song, Y., Wong, C., & Chang, D. D. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010201)80:2 · Cited by 26
Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor γ activation induced by 15-deoxyΔ12,14-prostaglandin J2 in neuroblastoma cells
RODWAY, H. A., Hunt, A. N., Kohler, J., Postle, A. D., & Lillycrop, K. A. (2004) · Biochemical Journal · doi:10.1042/bj20040107 · Cited by 23
Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells.
Posch, M. G., Zang, C., Mueller, W. C., Laß, U., von Deimling, A., & Elstner, E. (2004) · PubMed · Cited by 22
The Cellular Response to PPARγ Ligands Is Related to the Phenotype of Neuroblastoma Cell Lines
Servidei, T., Roberta Morosetti, A., Ferlini, C., Cusano, G., Scambia, G., Mastrangelo, R., & Koeffler, H. P. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040041292297 · Cited by 20
Arachidonic acid increases choline acetyltransferase activity in spinal cord neurons through a protein kinase C‐mediated mechanism
Chalimoniuk, M., King‐Pospisil, K., Pedersen, W. A., Małecki, A., Wylęgała, E., Mattson, M. P., Hennig, B., & Toborek, M. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02535.x · Cited by 17
Human glioblastoma ADF cells express tyrosinase, L ‐tyrosine hydroxylase and melanosomes and are sensitive to L ‐tyrosine and phenylthiourea
Bonfigli, A., Zarivi, O., Colafarina, S., Cimini, A., Ragnelli, A. M., Aimola, P., Natali, P. G., Cerù, M. P., Amicarelli, F., & Miranda, M. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20603 · Cited by 15
Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression
Emmans, V. C., RODWAY, H. A., Hunt, A. N., & Lillycrop, K. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320840 · Cited by 15
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7
Self-citation
P1-397 Pioglitazone in Alzheimer's disease: rationale and clinical trial design
Geldmacher, D., & Landreth, G. E. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80709-7 · Cited by 2
Self-citation

Sorted by citations

Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,075
The Peroxisome Proliferator-Activated Receptor: A Family of Nuclear Receptors Role in Various Diseases
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
de la Monte, S. M. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 468

See all 319

Authors: HENEKA, M., & LANDRETH, G.
Affiliations: University of Münster (DE)
Case Western Reserve University (US)
Corresponding author: HENEKA, M
ORCID: HENEKA, M
LANDRETH, G
Venue: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher: Elsevier BV
Published: 2007-08
Volume: 1771
Issue: 8
Pages: 1031-1045
ISSN: 1388-1981 (ISSN-L)
DOI: 10.1016/j.bbalip.2007.04.016
OpenAlex: W2054685711
Cited by: 317
References: 181
Citations by year: 2026: 4 · 2025: 13 · 2024: 16 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 20 · 2018: 13 · 2017: 20 · 2016: 17 · 2015: 16 · 2014: 21 · 2013: 18 · 2012: 21
FWCI: 9.13
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (publishedVersion)
PubMed (publishedVersion)
Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: peroxisome proliferator-activated receptors, PPARγ, brain, neuroinflammation, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, neurodegeneration, amyloid-beta, nonsteroidal anti-inflammatory drugs, PPAR agonists, neuroprotection, central nervous system development
MeSH terms: Animals, Brain, Brain Neoplasms, Central Nervous System Diseases, Brain Ischemia, Encephalomyelitis, Autoimmune, Experimental, Humans, Neurodegenerative Diseases, Peroxisome Proliferator-Activated Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PPARs in the brain

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks